Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase EARLY_PHASE1 × Prostatic Neoplasms × relugolix × Clear all

Phase

Phase 2 22 Phase 3 5 Phase 1 3 Phase EARLY_PHASE1 1 Phase 2/3 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 1

Interventions

Magnetic Resonance Spectroscopy 9 gallium 68 PSMA-11 7 Specimen Handling 4 2-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid 4 enzalutamide 2 bicalutamide 2 acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 2 Standard of Care 2 Radiation 2 Positron Emission Tomography Computed Tomography 2 HhAntag691 2 Abiraterone Acetate 2 68Ga-DKFZ-PSMA-11 2 2-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole 2 xentuzumab 1 trastuzumab biosimilar HLX02 1 tislelizumab 1 teprotumumab 1 tazemetostat 1 relugolix 1 pertuzumab 1 palbociclib 1 olaparib 1 niraparib 1 gallium citrate 1 eribulin 1 entrectinib 1 darolutamide 1 cobimetinib 1 atezolizumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07069465 2025-07-16

PIONEER PSMA

Urology Clinics of North Texas

Phase EARLY_PHASE1 Completed

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡